Margaret Centenera

Research Interests

Cancer Biology and Clinical Oncology Men's Health Translational Health Outcomes Biomarkers Cancer Cell Biology Cancer Therapy

Dr Margaret Centenera

Externally Funded Research Fellow (C)

SAIGENCI

College of Health

Eligible to supervise Masters and PhD - email supervisor to discuss availability.

Dr Centenera is a Research Fellow in the Prostate Cancer Research Group located at the South Australian Health and Medical Research Institute. Her research is focused on improving treatments for men with prostate cancer. This involves understanding and targeting the androgen receptor in prostate cancer cells, and identifying more accurate markers for monitoring patient response to current and emerging prostate cancer therapeutics. Dr Centenera is an expert in patient-derived explants as a preclinical model of prostate cancer.

 

Date Position Institution name
2016 - ongoing Research Fellow University of Adelaide
2013 - 2015 Prostate Cancer Foundation of Australia Young Investigator University of Adelaide
2008 - 2012 Postdoctoral Research Officer University of Adelaide
2007 - 2008 Research Associate University of Adelaide

Date Type Title Institution Name Country Amount
2016 Invitation Markers in Cancer Diagnostic Development Tutorial American Society of Clinical Oncology United States -
2015 Award School of Medicine Travel Grant University of Adelaide Australia -
2013 Award Beat Cancer Project Travel Award South Australia Heart and Medical Research Institute Australia -
2012 Fellowship School of Medicine Travel Grants University of Adelaide Australia -
2010 Award Travel Grant Prostate Cancer Foundation of Australia Australia -
2008 Recognition Letter of Commendation-PhD Thesis Examiner University of Adelaide Australia -
2006 Award School of Molecular and Biomedical Science Postgraduate Conference Travel Award University of Adelaide Australia -
2004 Award Travel Award The Lorne Cancer Conference - -
2004 Scholarship Faculty of Health Sciences PhD Scholarship University of Adelaide Australia -
2003 Scholarship Honours Research Scholarhip The Queen Elizabeth Hospital Australia -
2003 Recognition Best Honours Presentation The Queen Elizabeth Hospital Australia -

Date Institution name Country Title
2004 - 2008 Department of Physiology Australia Doctor of Philosophy
2003 - 2003 Department of Physiology Australia Bachelor of Science with First Class Honours
1997 - 2001 University of Adelaide Australia Bachelor of Health Science

Year Citation
2024 Lin, H. -M., Yang, X., Centenera, M. M., Huynh, K., Giles, C., Dehairs, J., . . . Horvath, L. G. (2024). Circulating Lipid Profiles Associated With Resistance to Androgen Deprivation Therapy in Localized Prostate Cancer. JCO Precision Oncology, 8(8), e2400260-1-e2400260-11.
DOI Scopus8 WoS8 Europe PMC7
2024 Rahman, R., Rahaman, M. H., Hanson, A. R., Choo, N., Hassankhani, R., Islam, S., . . . Selth, L. A. (2024). CDK9 inhibition inhibits multiple oncogenic transcriptional and epigenetic pathways in prostate cancer. British Journal of Cancer, 131(6), 1092-1105.
DOI Scopus3 WoS4 Europe PMC5
2024 Rahman, R., Rahaman, M. H., Hanson, A. R., Choo, N., Xie, J., Townley, S. L., . . . Selth, L. A. (2024). Author Correction: CDK9 inhibition constrains multiple oncogenic transcriptional and epigenetic pathways in prostate cancer.. Br J Cancer, 131(10), 1719.
DOI WoS1 Europe PMC1
2023 Shin, S. Y., Centenera, M. M., Hodgson, J. T., Nguyen, E. V., Butler, L. M., Daly, R. J., & Nguyen, L. K. (2023). A Boolean-based machine learning framework identifies predictive biomarkers of HSP90-targeted therapy response in prostate cancer. Frontiers in Molecular Biosciences, 10, 1094321-1-1094321-16.
DOI Scopus7 WoS6 Europe PMC5
2023 Hinneh, J. A., Gillis, J. L., Mah, C. Y., Irani, S., Shrestha, R. K., Ryan, N. K., . . . Butler, L. M. (2023). Targeting hyaluronan-mediated motility receptor (HMMR) enhances response to androgen receptor signalling inhibitors in prostate cancer. British Journal of Cancer, 129(8), 1350-1361.
DOI Scopus11 WoS12 Europe PMC11
2022 Centenera, M. M., Vincent, A. D., Moldovan, M., Lin, H. M., Lynn, D. J., Horvath, L. G., & Butler, L. M. (2022). Harnessing the Heterogeneity of Prostate Cancer for Target Discovery Using Patient-Derived Explants. Cancers, 14(7), 1-18.
DOI Scopus13 WoS13 Europe PMC15
2022 Hinneh, J. A., Gillis, J. L., Moore, N. L., Butler, L. M., & Centenera, M. M. (2022). The role of RHAMM in cancer: Exposing novel therapeutic vulnerabilities. Frontiers in Oncology, 12, 1-14.
DOI Scopus26 WoS25 Europe PMC25
2021 Kwan, K. H., Burvenich, I. J. G., Centenera, M. M., Goh, Y. W., Rigopoulos, A., Dehairs, J., . . . Ackermann, U. (2021). Synthesis and fluorine-18 radiolabeling of a phospholipid as a PET imaging agent for prostate cancer. Nuclear medicine and biology, 93, 37-45.
DOI Scopus4 WoS3 Europe PMC3
2021 Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S., . . . Swinnen, J. V. (2021). Lipidomic profiling of clinical prostate cancer reveals targetable alterations in membrane lipid composition. Cancer Research, 81(19), 4981-4993.
DOI Scopus63 WoS62 Europe PMC62
2021 Centenera, M. M., Scott, J. S., Machiels, J., Nassar, Z. D., Miller, D. C., Zinonos, I., . . . Butler, L. M. (2021). ELOVL5 is a critical and targetable fatty acid elongase in prostate cancer. Cancer Research, 81(7), 1704-1718.
DOI Scopus71 WoS68 Europe PMC70
2021 Lin, H. -M., Huynh, K., Kohli, M., Tan, W., Azad, A. A., Yeung, N., . . . Horvath, L. G. (2021). Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer. Prostate Cancer and Prostatic Diseases, 24(3), 860-870.
DOI Scopus24 WoS26 Europe PMC24
2021 Gillis, J. L., Hinneh, J. A., Ryan, N. K., Irani, S., Moldovan, M., Quek, L. -E., . . . Butler, L. M. (2021). A feedback loop between the androgen receptor and 6-phosphogluoconate dehydrogenase (6PGD) drives prostate cancer growth. eLife, 10, e62592-1-e62592-27.
DOI Scopus27 WoS28 Europe PMC31
2020 Scheinberg, T., Kench, J., Stockler, M., Mahon, K. L., Sebastian, L., Stricker, P., . . . Horvath, L. G. (2020). Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer). BMJ Open, 10(1), e033667-1-e033667-6.
DOI Scopus14 WoS13 Europe PMC12
2020 Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., . . . Butler, L. M. (2020). Fatty acid oxidation is an adaptive survival pathway induced in prostate tumors by heat shock protein 90 inhibition. Molecular cancer research : MCR, 18(10), 1500-1511.
DOI Scopus19 WoS18 Europe PMC19
2020 Nassar, Z. D., Mah, C. Y., Dehairs, J., Burvenich, I. J., Irani, S., Centenera, M. M., . . . Butler, L. M. (2020). Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis. Elife, 9, 1-34.
DOI Scopus151 WoS148 Europe PMC150
2019 Nassar, Z., Mah, C. Y., Dehairs, J., Burvenich, I. J. G., Irani, S., Centenera, M., . . . Butler, L. (2019). DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis.
DOI
2019 Balaban, S., Nassar, Z. D., Zhang, A. Y., Hosseini-Beheshti, E., Centenera, M. M., Schreuder, M., . . . Hoy, A. J. (2019). Extracellular fatty acids are the major contributor to lipid synthesis in prostate cancer. Molecular Cancer Research, 17(4), 949-962.
DOI Scopus68 WoS67 Europe PMC68
2019 Mutuku, S. M., Trim, P. J., Prabhala, B. K., Irani, S., Bremert, K. L., Logan, J. M., . . . Butler, L. M. (2019). Evaluation of small molecule drug uptake in patient-derived prostate cancer explants by mass spectrometry. Scientific Reports, 9(1), 15008.
DOI Scopus14 WoS13 Europe PMC12
2018 Lin, H., Lee, B., Castillo, L., Spielman, C., Grogan, J., Yeung, N., . . . Daly, R. (2018). Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer. The Prostate, 78(4), 308-317.
DOI Scopus59 WoS60 Europe PMC53
2018 Armstrong, H., Gillis, J., Johnson, I., Nassar, Z., Moldovan, M., Levrier, C., . . . Butler, L. (2018). Dysregulated fibronectin trafficking by Hsp90 inhibition restricts prostate cancer cell invasion. Scientific reports, 8(1), 2090-1-2090-14.
DOI Scopus32 WoS32 Europe PMC30
2018 Centenera, M., Selth, L., Ebrahimie, E., Butler, L., & Tilley, W. (2018). New opportunities for targeting the androgen receptor in prostate cancer. Cold Spring Harbor Perspectives in Medicine, 10(12), 1-19.
DOI Scopus24 WoS21 Europe PMC21
2018 Nguyen, E., Centenera, M., Moldovan, M., Das, R., Irani, S., Vincent, A., . . . Butler, L. (2018). Identification of novel response and predictive biomarkers to Hsp90 inhibitors through mass spectrometry-based proteomic profiling of patient-derived prostate tumor explants. Molecular & cellular proteomics : MCP, 17(8), 1470-1486.
DOI Scopus30 WoS31 Europe PMC29
2018 Shafi, A., Schiewer, M., de Leeuw, R., Dlygeri, E., McCue, P., Shah, N., . . . Knudsen, K. (2018). Novel patient derived models reveal the impact of the tumor microenvironment on therapeutic response. European Urology Oncology, 1(4), 325-337.
DOI Scopus39 WoS41 Europe PMC42
2018 Centenera, M. M., Hickey, T. E., Jindal, S., Ryan, N. K., Ravindranathan, P., Mohammed, H., . . . Tilley, W. D. (2018). A patient-derived explant (PDE) model of hormone-dependent cancer. Molecular Oncology, 12(9), 1608-1622.
DOI Scopus101 WoS99 Europe PMC99
2017 Selth, L., Das, R., Townley, S., Coutinho, I., Hanson, A., Centenera, M., . . . Tilley, W. (2017). A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer. Oncogene, 36(1), 24-34.
DOI Scopus95 WoS94 Europe PMC85
2017 Tran, L. N., Kichenadasse, G., Butler, L. M., Centenera, M. M., Morel, K. L., Ormsby, R. J., . . . Sykes, P. J. (2017). The combination of metformin and valproic acid induces synergistic apoptosis in the presence of p53 and androgen signaling in prostate cancer. Molecular cancer therapeutics, 16(12), 2689-2700.
DOI Scopus28 WoS27 Europe PMC19
2016 Armstrong, H., Koay, Y., Irani, S., Das, R., Nassar, Z., The Australian Prostate Cancer BioResource., . . . Butler, L. (2016). A novel class of Hsp90 C-terminal modulators have pre-clinical efficacy in prostate tumor cells without induction of a heat shock response. Prostate, 76(16), 1546-1559.
DOI Scopus23 WoS23 Europe PMC23
2016 Carter, S., Centenera, M., Tilley, W., Selth, L., & Butler, L. (2016). IκBα mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor. BMC Cancer, 16(1), 141-1-141-13.
DOI Scopus12 WoS11 Europe PMC7
2016 Carter, S. L., Centenera, M. M., Tilley, W. D., Selth, L. A., & Butler, L. M. (2016). Erratum to: IΚBα mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor.[BMC Cancer. 2016] 16:141. Doi: 10.1186/s12885-016-2188-2.. BMC Cancer, 16(1), 1 page.
DOI Europe PMC1
2016 Butler, L., Centenera, M., & Swinnen, J. (2016). Androgen control of lipid metabolism in prostate cancer: novel insights and future applications. Endocrine-Related Cancer, 23(5), 219-227.
DOI Scopus105 WoS98 Europe PMC91
2015 Centenera, M., Carter, S., Gillis, J., Marrocco-Tallarigo, D., Grose, R., Tilley, W., & Butler, L. (2015). Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms. Endocrine-Related Cancer, 22(5), 805-818.
DOI Scopus26 WoS27 Europe PMC26
2015 Butler, L., Ferraldeschi, R., Armstrong, H., Centenera, M., & Workman, P. (2015). Maximizing the therapeutic potential of HSP90 inhibitors. Molecular Cancer Research, 13(11), 1445-1451.
DOI Scopus173 WoS172 Europe PMC156
2013 Centenera, M., Fitzpatrick, A., Tilley, W., & Butler, L. (2013). Hsp90: still a viable target in prostate cancer. Biochimica et Biophysica Acta-Reviews on Cancer, 1835(2), 211-218.
DOI Scopus46 WoS43 Europe PMC36
2013 Comstock, C., Augello, M., Goodwin, J., de Leeuw, R., Schiewer, M., Ostrander, W., . . . Knudsen, K. (2013). Targeting cell cycle and hormone receptor pathways in cancer. Oncogene, 32(48), 5481-5491.
DOI Scopus100 WoS89 Europe PMC86
2013 Centenera, M., Raj, G., Knudsen, K., Tilley, W., & Butler, L. (2013). Ex vivo culture of human prostate tissue and drug development. Nature Reviews, Urology, 10(8), 483-487.
DOI Scopus117 WoS113 Europe PMC110
2013 Gillis, J., Selth, L., Centenera, M., Townley, S., Sun, S., Plymate, S., . . . Butler, L. (2013). Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors. Oncotarget, 4(5), 691-704.
DOI Scopus51 WoS50 Europe PMC44
2013 Ravindranathan, P., Lee, T., Yang, L., Centenera, M., Butler, L., Tilley, W., . . . Raj, G. (2013). Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer. Nature Communications, 4(5), 1923-1-1923-11.
DOI Scopus128 WoS127 Europe PMC119
2012 Schiewer, M., Goodwin, J., Han, S., Brenner, J., Augello, M., Dean, J., . . . Knudsen, K. (2012). Dual roles of PARP-1 promote cancer growth and progression. Cancer Discovery, 2(12), 1134-1149.
DOI Scopus379 WoS374 Europe PMC345
2012 Centenera, M., Gillis, J., Hanson, A., Jindal, S., Taylor, R., Risbridger, G., . . . Butler, L. (2012). Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. Clinical Cancer Research, 18(13), 3562-3570.
DOI Scopus96 WoS94 Europe PMC91
2011 Chiam, K., Centenera, M., Butler, L., Tilley, W., & Bianco-Miotto, T. (2011). GSTP1 DNA methylation and expression status is indicative of 5-aza-2'-deoxycytidine efficacy in human prostate cancer cells. PLoS One, 6(9), e25634-1-e25634-11.
DOI Scopus47 WoS39 Europe PMC35
2009 Marrocco, D., Centenera, M., Scher, H., Tilley, W., & Butler, L. (2009). Finding the place of histone deacetylase inhibitors in prostate cancer therapy. Expert Review of Clinical Pharmacology, 2(6), 619-630.
DOI Scopus5 Europe PMC4
2009 Peters, A., Buchanan, G., Ricciardelli, C., Bianco-Miotto, T., Centenera, M., Harris, J., . . . Tilley, W. (2009). Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Research, 69(15), 6131-6140.
DOI Scopus345 WoS322 Europe PMC271
2008 Centenera, M., Harris, J., Tilley, W., & Butler, L. (2008). The Contribution of Different Androgen Receptor Domains to Receptor Dimerization and Signaling. Molecular Endocrinology, 22(11), 2373-2382.
DOI Scopus125 WoS113 Europe PMC96
2006 Butler, L., Centenera, M., Neufing, P., Buchanan, G., Choong, C., Ricciardelli, C., . . . Tilley, W. (2006). Suppression of androgen receptor signaling in prostate cancer cells by an inhibitory receptor variant. Molecular Endocrinology, 20(5), 1009-1024.
DOI Scopus15 WoS14 Europe PMC14

Year Citation
2025 Scheinberg, T., Kench, J. G., Ferguson, P., Sutherland, S., Stockler, M. R., Mahon, K. L., . . . Horvath, L. (2025). LEEP: A randomised, window of opportunity, neoadjuvant trial examining the pharmacodynamic effects of ribociclib prior to radical prostatectomy for high-risk, localised prostate cancer.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 43 (pp. 1 page). LIPPINCOTT WILLIAMS & WILKINS.
DOI
2017 Nassar, Z. D., Centenera, M. M., Machiels, J., Polacek, S. J., Bloch, K., Tilley, W. D., . . . Butler, L. (2017). Lipid elongation: an unexplored therapeutic target in prostate cancer. In CANCER RESEARCH Vol. 77 (pp. 2 pages). Washington, DC: AMER ASSOC CANCER RESEARCH.
DOI
2017 Tran, L. N. K., Kichenadasse, G., Ormsby, R. J., Morel, K. L., Butler, L. M., Centenera, M. M., & Sykes, P. J. (2017). COMBINATION OF METFORMIN AND SODIUM VALPROATE FOR PROSTATE CANCER: A RAPID APPROACH FROM BENCH TO CLINICAL TRIAL.. In JOURNAL OF UROLOGY Vol. 197 (pp. E1108-E1109). Boston, MA: ELSEVIER SCIENCE INC.
DOI
2009 Butler, L., Centenera, M., Marrocco, D., Carter, S., Bianco-Miotto, T., & Tilley, W. (2009). A novel combinatorial approach using androgen receptor-targeted agents for treatment of prostate cancer. In Cancer Research Vol. 69 (pp. 2 pages). American Association for Cancer Research.

Year Citation
2022 Strach, M. C., Yeung, N., Lin, H. -M., Ansari, N., Koh, C., Shin, J. -S., . . . Mahon, K. (2022). Patient-derived explant model of appendiceal cancer.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS.
2020 Lin, H. -M., Huynh, K., Kohli, M., Tan, W., Azad, A., Yeung, N., . . . Horvath, L. (2020). Lipidomic analysis of circulating lipids across the natural history of prostate cancer identifies aberrant ceramide metabolism. Poster session presented at the meeting of Abstracts of the Mini Annual Scientific Meeting ANZUP 2020, as published in Asia-Pacific Journal of Clinical Oncology. Adelaide, SA: Wiley.
2020 Butler, L. M., Mah, C. Y., Dehairs, J., Vincent, A., Mutuku, S., Spotbeen, X., . . . Swinnen, J. (2020). Phospholipid profiling of clinical prostate tissues reveals targetable alterations in membrane lipid composition accompanying tumorigenesis. Poster session presented at the meeting of CANCER RESEARCH. ELECTR NETWORK: AMER ASSOC CANCER RESEARCH.
DOI WoS1
2020 Mah, C. Y., Nassar, Z. D., Burvenich, I. J., Irani, S., Centenera, M. M., Moldovan, M., . . . Butler, L. M. (2020). DECR1: The rate limiting enzyme of polyunsaturated fatty acid metabolism and a novel therapeutic target in prostate cancer. Poster session presented at the meeting of CANCER RESEARCH. ELECTR NETWORK: AMER ASSOC CANCER RESEARCH.
DOI
2019 Scheinberg, T., Kench, J., Stockler, M., Mahon, K. L., Sebastian, L., Stricker, P., . . . Horvath, L. G. (2019). Pharmacodynamics Effects of CDK4/6 Inhibitor LEE011 (Ribociclib) in High-Risk, Localised Prostate Cancer: A Study Protocol for a Randomised Controlled Phase II Trial (Leep Study). Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY.
2019 Butler, L., Irani, S., Centenera, M., Ryan, N., Pegg, N., & Brooks, A. N. (2019). Preclinical investigation of a small molecule inhibitor of p300/CBP reveals efficacy in patient-derived prostate tumor explants.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
DOI WoS2
2018 Mutuku, S. M., Centenera, M. M., Trim, P. J., Snel, M. F., & Butler, L. M. (2018). Evaluation of small molecule drug uptake in <i>ex vivo</i> cultured clinical prostate tumours by mass spectrometry. Poster session presented at the meeting of BJU INTERNATIONAL. Brisbane, AUSTRALIA: WILEY.
2018 Nassar, Z. D., Centenera, M. M., Machiels, J., Zinonos, I., Hanson, A., Bloch, K., . . . Swinnen, J. V. (2018). Lipid elongation in prostate cancer is androgen regulated and a potential therapeutic target. Poster session presented at the meeting of BJU International. Brisbane, Australia: Wiley.
2017 Mutuku, S. M., Prabhala Bala., Centenera, M., Trim, P., Snel, M., & Butler, L. (2017). Quantification of Enzalutamide in Cultured Prostate Tissue Using LC-MS/MS. Poster session presented at the meeting of 26th Australian and New Zealand Society for Mass Spectrometry. Flinders University.
2017 Mutuku, S. M., Centenera, M., Trim, P., Gustafsson, O. J., Snel, M., & Butler, L. (2017). A Mass Spectrometry Approach to Characterise Lipid Composition in Prostate Tumuors. Poster session presented at the meeting of 11th Florey Postgraduate Research Conference. Adelaide.
2016 Nassar, Z. D., Centenera, M. M., Machiels, J., Polacek, S. J., Bloch, K., Tilley, W. D., . . . Swinnen, J. V. (2016). Androgenic regulation of lipid elongation in prostate cancer. Poster session presented at the meeting of BJU International. Melbourne: Wiley.
2015 Armstrong, H., Butler, L., Selth, L., Tarulli, G., & Centenera, M. (2015). The Hsp90 inhibitor, NVP-AUY922, produces anti-tumour activity through inhibition of fibronectin polymerization resulting in cytoskeletal reorganization. Poster session presented at the meeting of BJU INTERNATIONAL. Cairns, AUSTRALIA: WILEY-BLACKWELL.
2010 Centenera, M. M., Treloar, J. L., Hanson, A., Sutherland, P., Tilley, W. D., & Butler, L. M. (2010). Evaluation of the synthetic heat shock protein 90 inhibitors NVP-AUY922 and NVP-HSP990 in human prostate cancer tissue. Poster session presented at the meeting of European Journal of Cancer Supplements. Berlin, Germany: Elsevier.
DOI
Date Project Investigators Funding body Amount
2023-2025 Targeting the metabolic adaptations that drive anti-androgen resistance in prostate cancer Holst J, Centenera MM Cancer Council NSW

$668,309
2023-2024 Unravelling the cellular and spatial heterogeneity in prostate cancer to unravel drivers of disease progression and treatment resistance. Mah CY, Centenera MM, Butler LM, Lynn DJ The Hospital Research Foundation $125,000
2022-2024 A patient-derived discovery platform for companion biomarker development in prostate cancer. Butler LM, Centenera MM, Horvath LG Cancer Council NSW $433,228
2021-2022 A patient-derived discovery platform for companion biomarker development in prostate cancer. Centenera MM, Butler LM, Horvath LG The Hospital Research Foundation $149,662
2019-2021 PRECEPT - PRostatE CancEr Prognosis and Treatment Corcorran N, Boutros P, Bristow R, Centenera MM, Collins I, Eeles R, Hayes V, Hovens C, Ijzerman M, Papenfuss T, Parker B, Park D, Pope B, Sweeney C, Tran B Movember Foundation - Prostate Cancer Research Alliance $5,250,000
2019 Generation of a protein signature of sensitivity in prostate cancer Centenera MM University of Adelaide $39,800

2018 - 2020

 Novel co-extinction strategies for treatment of prostate cancer Butler LM, Lynn DJ, Hayes VM, Horvath LG, Mills IG, Centenera MM Cancer Australia $596,409
2015 - 2017 Exploiting alterations in lipid metabolism to improve diagnosis, treatment and molecular imaging of prostate cancer

Butler LM, Swinnen JV, Tilley WD, Scott AM, Hoy AJ and Wittert GA

Co-Leads: Centenera MM, Selth LA, Dhomen N, Soekmadji C

 Movember Foundation / Prostate Cancer Foundation of Australia (MRTA3 $3,250,000
2015 - 2017 Molecular hallmarks of heat shock protein 90 inhibition in prostate cancer Butler LM, Daly R, Tilley WD, Horvath LG, Centenera MM Cancer Australia (APP1085471) $553,483 
2013 - 2015 Explant technology for biomarker discovery of androgen receptor targeted therapies

Centenera MM

 Prostate Cancer Foundation of Australia Young Investigator Grant (YIG0412) $450,000
2013 Evaluation of biomarkers of response to Hsp90 inhibition in human prostate cancer Centenera MM and Butler LM Royal Adelaide Hospital Clinical Project Grant $40,000
2012 - 2014 Exploiting metabolic alterations to more accurately monitor prostate cancer therapy Butler LM, Centenera MM, Claessens F, Swinnen J Prostate Cancer Foundation of Australia New Directions Development Award (NDDA 2711)

$299,817  
2011 Identification of biomarkers of response to Hsp90 inhibition in human prostate cancer. Centenera MM, Butler LM and Tilley WD. Royal Adelaide Hospital Clinical Project Grant $25,000

 

Medical students

Alyssa Fitzpatrick (co-supervisor), Summer Scholarship (2010), MBBS Year 4&5 Research component (2010-11), University of Adelaide

Undergraduate student co-supervision of laboratory-based research projects

Sean Burton (2007) Physiology III, Bachelor of Science, University of Adelaide

MJ Vink, BJ Rositano, EF Jackson (2011) Structural Cell Biol III, Bachelor of Science, University of Adelaide

Shinjie Wong (2013) Summer Scholarship, University of Adelaide

Roseanna Hunter (2014) Summer Scholarship, Freemasons Foundation Centre for Men’s Health, University of Adelaide

K Bremert, C Webber, L Day (2015) Investigative Cell Biol II, Bachelor of Science, University of Adelaide

Kayla Bremert (2016) Summer Scholarship, University of Adelaide

Joshua Hodgson (2019) Summer Scholarship, University of Adelaide

Teaching & assessment

Practical supervisor/tutor/assessor (2004) University of Adelaide, Bachelor of Science, Biology I

Practical supervisor/tutor/assessor (2005) University of Adelaide, Bachelor of Science, Physiology III

Examiner Honours students (2007-10) University of Adelaide, Department of Obstetrics and Gynaecology

Poster award judge (2009-11) The Australian Society for Medical Research, South Australian Meeting

Examiner Honours students (2020-2021) University of Adelaide, BHMSc

Guest lecturer (2016-current) University of Adelaide, School of Medicine, Integrative Cell Biology III

Date Role Research Topic Program Degree Type Student Load Student Name
2021 - 2025 Principal Supervisor Response and resistance to cyclin-dependent kinase 4/6 inhibition in prostate cancer Doctor of Philosophy Doctorate Full Time Mr Joshua Thomas Hodgson
2020 - 2024 Principal Supervisor Investigating How Fatty Acid Elongation Promotes Prostate Carcinogenesis Doctor of Philosophy Doctorate Full Time Miss Deanna Catherine Miller
2018 - 2024 Co-Supervisor Novel co-targets to improve androgen receptor inhibition in prostate cancer Doctor of Philosophy under a Jointly-awarded Degree Agreement with Doctorate Full Time Miss Josephine Ataa Hinneh
2013 - 2016 Co-Supervisor Elucidating the Molecular Action of Synthetic Heat Shock Protein 90 Inhibitors in Prostate Cancer Doctor of Philosophy Doctorate Full Time Miss Heather Krista Armstrong

Date Role Committee Institution Country
2023 - ongoing Member Cancer Council Postdoctoral Research Fellowship Grant Assessment Committee Cancer Council Victoria Australia
2016 - ongoing Member School of Medicine Early/Mid-Career Research Committee University of Adelaide Australia
2015 - ongoing Member Faculty of Health Sciences Low Risk Human Research Ethics Committee University of Adelaide Australia

Connect With Me

External Profiles

Other Links